Mesoblast discusses financial results and operational highlights in webcast

From GlobeNewswire: 2025-02-25 18:13:57

Mesoblast Limited will host a webcast on February 26th to discuss operational highlights and financial results for the half year ended December 31, 2024. The company is a global leader in allogeneic cellular medicines for inflammatory diseases. Mesoblast’s RYONCIL® is the first FDA-approved mesenchymal stromal cell therapy for pediatric patients with steroid-refractory acute graft versus host disease. The company is also developing additional cell therapies for various inflammatory conditions using its proprietary technology platforms. Mesoblast has a strong global intellectual property portfolio and proprietary manufacturing processes to produce off-the-shelf cellular medicines.



Read more at GlobeNewswire: Mesoblast Financial Results and Corporate Update Webcast